Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric ponatinib study in recurrent or refractory leukemias, lymphomas, and solid tumors
NL-OMON60305Phase 2Recruiting
- Sponsor
- Incyte
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ponatinib in chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 4 more (3 arms), sponsored by Incyte. Primary endpoints: Dose-limiting toxicities, Major cytogenetic response and 4 more. Started Feb 2020; status: recruiting.
02
Drugs
ponatinib
03
Conditions
chronic myelogenous leukemia (CML)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)leukemialymphoma
Beyond the preview
Go deeper on NL-OMON60305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60305.